Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Crovalimab (Synonyms: SKY59, SKY 59, RO7112689, RO 7112689)

Catalog No. T77190 Copy Product Info
🥰Excellent
Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Crovalimab

Copy Product Info
🥰Excellent
Catalog No. T77190
Synonyms SKY59, SKY 59, RO7112689, RO 7112689

Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Crovalimab
Cas No. 1917321-26-6
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$247-In Stock
5 mg$647-In Stock
10 mg$987-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:≥95% (SDS-PAGE); 99.68% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
In vivo
Method:
In cynomolgus monkeys, the pharmacodynamic and pharmacokinetic profiles of a single intravenous dose of Crovalimab (20 mg/kg) and its IgG1 derivative SG115 were evaluated. A multiple dosing regimen (intravenous/subcutaneous) was also used to assess immunological and serological responses.

Result:
A single dose of Crovalimab inhibited plasma C5 accumulation and sustained complement suppression for up to 8 weeks. SG115 showed a slow clearance rate (1.87 mL/day/kg). The multiple-dose regimen led to increased hemolytic activity, dysphagia, and elevated LDH and ALT levels.[1]
SynonymsSKY59, SKY 59, RO7112689, RO 7112689
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetComplement C5
Chemical Properties
Molecular Weight~150 kDa
Cas No.1917321-26-6
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Crovalimab | purchase Crovalimab | Crovalimab cost | order Crovalimab | Crovalimab in vivo | Crovalimab molecular weight